Deoxyribonucleic Acid (DNA) Manufacturing Market Report 2025

The deoxyribonucleic acid (DNA) manufacturing market size has grown rapidly in recent years. It will grow from $4.77 billion in 2024 to $5.58 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth during the historic period can be attributed to the rise of genomics-based research, expansion of the biotechnology and biopharma sectors, increasing number of contract manufacturing organizations (CMOs), growth in CRISPR and gene-editing applications, and supportive government funding and initiatives.

The deoxyribonucleic acid (DNA) manufacturing market size is expected to see rapid growth in the next few years. It will grow to $10.28 billion in 2029 at a compound annual growth rate (CAGR) of 16.5%. The growth during the forecast period can be attributed to the expansion of cell and gene therapy pipelines, increased drug discovery activities, rising biodefense initiatives, greater spending on pandemic preparedness, and the globalization of biomanufacturing supply chains. Key trends in this period include integration with next-generation sequencing (NGS), advancements in mRNA and DNA vaccines, improvements in long-read and high-fidelity DNA synthesis, increased use of automation and robotics in DNA manufacturing, and the development of next-generation enzymatic DNA synthesis (EDS).

The growing demand for gene therapies is expected to drive the expansion of the deoxyribonucleic acid (DNA) manufacturing market in the coming years. Gene therapies involve techniques that modify or replace defective genes to treat or prevent diseases, while personalized medicine focuses on tailoring medical treatments to an individual’s genetic, biological, and lifestyle characteristics. The increasing demand for gene therapies is largely fueled by the rising prevalence of genetic disorders, including cystic fibrosis, sickle cell anemia, and certain inherited forms of blindness. DNA manufacturing supports gene therapies by supplying high-quality, custom DNA sequences required to develop and deliver therapeutic genes capable of correcting or replacing faulty genetic material in patients. For example, in August 2024, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported that the number of individuals eligible for gene therapy treatments in the UK is projected to increase from 2,500 in 2021 to as many as 10,000 annually by 2028. Consequently, the growing demand for gene therapies is driving the growth of the DNA manufacturing market.

Key players in the DNA manufacturing market are concentrating on innovative approaches, such as GMP-grade plasmid DNA production, to improve the quality, safety, and scalability of gene and cell therapy applications. GMP-grade plasmid DNA production involves manufacturing plasmid DNA under Good Manufacturing Practice (GMP) conditions, which are regulatory standards ensuring the quality, safety, and consistency of biopharmaceutical products. For instance, in April 2025, ProBio Genomics Inc., a US-based contract development and manufacturing organization (CDMO), launched GMP Plasmid DNA Manufacturing Services in Hopewell, offering in-house analytical testing, method development, and project management. The service provides unique advantages, including end-to-end process development, analytical testing, method optimization, and project oversight, eliminating the need for multiple suppliers and accelerating development timelines. It ensures high-quality output with ≥85% supercoiled plasmid DNA content while minimizing contamination risks. ProBio also offers GMP-like plasmids with a four-week delivery timeline and full GMP-grade plasmids within three months.

In December 2022, Polyplus-transfection S.A., a France-based biotechnology company, acquired Xpress Biologics S.A. for an undisclosed amount. Through this acquisition, Polyplus aims to expand its plasmid DNA and protein production capabilities to support advanced therapy applications, including gene therapy, mRNA, and viral vector manufacturing. Xpress Biologics S.A., based in Belgium, provides DNA manufacturing services.

Major players in the deoxyribonucleic acid (DNA) manufacturing market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Kaneka Corporation, Catalent Inc., Charles River Laboratories International Inc., WuXi Biologics Inc., AGC Biologics Inc., Integrated DNA Technologies Inc., GenScript Biotech Corporation, Takara Bio USA Inc., Twist Bioscience Corp., Ajinomoto Bio-Pharma Services, OriGene Technologies Inc., DNA Script SAS, Eurofins Genomics LLC, Touchlight Genetics Ltd., Elegen Inc., VGXI Inc., PlasmidFactory GmbH & Co. KG.

North America was the largest region in the deoxyribonucleic acid (DNA) manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in deoxyribonucleic acid (DNA) manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the deoxyribonucleic acid (DNA) manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Deoxyribonucleic acid (DNA) manufacturing refers to the artificial creation or replication of DNA sequences using advanced biochemical techniques. This process involves synthesizing specific nucleotide sequences or amplifying existing DNA strands to generate large quantities of genetic material with high accuracy and purity.

The primary types of DNA manufacturing include plasmid DNA, synthetic DNA, gene synthesis, and oligonucleotide synthesis. Plasmid DNA is a small, circular, double-stranded DNA molecule that exists independently of a cell’s chromosomal DNA. The products are available in multiple grades, including good manufacturing practices (GMP) grade and research and development grade, and are distributed for applications such as cell and gene therapy, vaccines, oligonucleotide-based drugs, and more. These services cater to end users including pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations.

The deoxyribonucleic acid (DNA) manufacturing market research report is one of a series of new reports that provides deoxyribonucleic acid (DNA) manufacturing market statistics, including deoxyribonucleic acid (DNA) manufacturing industry global market size, regional shares, competitors with a deoxyribonucleic acid (DNA) manufacturing market share, deoxyribonucleic acid (DNA) manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the deoxyribonucleic acid (DNA) manufacturing industry. This deoxyribonucleic acid (DNA) manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The deoxyribonucleic acid (DNA) manufacturing market consists of sales of synthetic DNA, plasmid DNA, linear DNA, oligonucleotides, and gene constructs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.